after PSGL-1 ligation have been identified. Using a combination of pharmacological and genetic tools, we have shown that the Src family kinase (SFK) members Hck, Fgr, and Lyn are required for αMβ2-dependent neutrophil recruitment by activated platelets along damaged arteries and for the subsequent development of intimal hyperplasia. 18 In these studies, proline-rich tyrosine kinase 2 (Pyk2) emerged as an important downstream regulator of αMβ2. [19] [20] [21] The binding of P-selectin to PSGL-1 also results in an SFK-dependent phosphorylation of Nef-associated factor 1, which is constitutively associated with the cytoplasmic domain of PSGL-1. Phosphorylated Nef-associated factor 1 recruits and activates phosphoinositide-3-kinase, which in turn mediates Mac-1 activation. 22 Thus, SFK influence multiple steps in the signaling cascade, leading to firm platelet-neutrophil interaction.
The SFK signaling pathway may therefore be a target to modulate neutrophil recruitment by platelets at the site of vascular injury. In many systems, cAMP-activated protein kinase A (PKA) inhibits SFK by upregulating C-terminal Src Kinase (Csk). PKA phosphorylation of Csk on serine 364 increases its activity, 23 resulting in Csk-mediated phosphorylation of SFK and downregulation of their activity. 24, 25 In T cells, activation of Csk by PKA blocks signaling by lymphoid cell-specific SFK (Lck) and reduces activation through the T-cell receptor. 26 In platelets, interaction between SFK and Csk modulates αIIbβ3 integrin signaling to the cytoskeleton. 27 Selective inactivation of Csk in myeloid cell increases neutrophil adhesion in vitro and inflammatory reactions in skin and lungs of mice, 28 indicating that Csk may be a crucial negative regulator of neutrophil function. In myeloid cells, cAMP levels and PKA activity are controlled by phosphodiesterase type 4 (PDE4). 29 The loss of Pde4d and Pde4b, which encode PDE4 isoforms D and B, respectively, impairs neutrophil migration at sites of inflammation in mice. 30 Similarly, selective PDE4 inhibitors also exert anti-inflammatory actions in animal models. [31] [32] [33] [34] [35] In this study, we sought to determine whether platelet P-selectin-mediated activation of neutrophil SFK is negatively regulated by cAMP-PKA-Csk signaling. In particular, we tested the hypothesis that selective PDE4 inhibition, by promoting the cAMP-PKA-Csk pathway, would upregulate an intrinsic signaling network that negatively regulates platelet-neutrophil interaction. We demonstrate that PDE4 blockade intercepts SFK signaling and curbs platelet-mediated neutrophil recruitment at the site of vascular injury, suggesting that PDE4 inhibitors may serve as a novel pharmacological strategy to prevent the detrimental vascular consequences of platelet-neutrophil interactions.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Selective PDE4 Blockade Inhibits SFK-Mediated Pyk2 Phosphorylation in Neutrophils Exposed to Soluble P-Selectin
SFK-mediated phosphorylation of Pyk2 is necessary to stabilize platelet-neutrophil adhesion initiated by the binding of platelet P-selectin to leukocyte PSGL-1. 16, 18 To determine whether the cAMP-PKA-Csk pathway negatively regulates SFK activity during platelet-neutrophil interactions, we tested the ability of the selective PDE4 inhibitor rolipram to alter Pyk2 phosphorylation in human neutrophils exposed to soluble P-selectin under stirring conditions. Pyk2 was immunoprecipitated from lysates and analyzed by Western blotting with an anti-phosphotyrosine antibody. Pyk2 phosphorylation was barely detectable in neutrophils stirred in the absence of P-selectin and increased ≈20-fold in the presence of P-selectin ( Figure 1A ). Pretreatment of neutrophils with rolipram essentially abolished P-selectin-mediated phosphorylation of Pyk2, suggesting that elevating neutrophil cAMP levels negatively regulates SKF activity in this system. The effect of rolipram was reversed by H89, a selective inhibitor of PKA activity, establishing a role for cAMP. In contrast, H89 had no effect on the ability of the SFK inhibitor PP2 to reduce Pyk2 phosphorylation, suggesting that PKA acts upstream of SFK. Similar results were obtained using RO1720/24 and PKI, selective inhibitors of PDE4 and PKA, respectively ( Figure III in the online-only Data Supplement). Using phosphospecific antibodies, we established that SFK phosphorylate tyrosine residues Tyr579 and Tyr580 within the activation loop of Pyk2 and that this phosphorylation was dose-dependently inhibited by rolipram ( Figure 1B ).
To confirm a role for PKA in neutrophil activation on binding to P-selectin, we analyzed the pattern of PKA-mediated protein phosphorylation with an antibody that selectively recognizes phosphorylated serines or threonines in the context of the PKA substrate motif K/RK/RXpS/pT. Rolipram treatment of neutrophils increased phosphorylation of several K/ RK/RXpS/pT-containing proteins. The effects of rolipram on K/RK/RXS/T phosphorylation were enhanced by calyculin A, an inhibitor of both phosphatase 1 and 2A, and reduced by H89. Specifically, Csk was identified as a major protein undergoing PKA-mediated phosphorylation in neutrophils treated with the PDE4 inhibitor ( Figure 2A ). The effect of rolipram on Csk phosphorylation was consistently greater in neutrophils activated by P-selectin than in unstimulated neutrophils, and PKA inhibition ablated rolipram-mediated Csk phosphorylation ( Figure 2B ). To demonstrate that phosphorylation of Csk was PKA-mediated, neutrophil lysates were subjected to immunoprecipitation using an anti-Csk antibody and immunoprecipitates were blotted with anti-K/RK/RXpS/ pT. The results, reported in Figure IV tail, we used a phospho-specific antibody to test whether selective PDE4 blockade enhances Tyr529 phosphorylation. Accordingly, treatment with rolipram increased phospho-Tyr529 ( Figure V in the online-only Data Supplement), confirming that the effect of PDE4 inhibition on SFK is likely mediated by Csk. These results support a model in which SFK signaling in neutrophils exposed to P-selectin is negatively regulated by PDE4 blockade through the cAMP-PKA-Csk pathway.
Effect of PDE Inhibitors on Neutrophil Adhesion to Activated Platelets in Mixed Cell Suspension and on Neutrophil Recruitment by Adherent Platelets Under Flow Conditions
We previously reported that SFK activation of Mac-1 is fundamentally important in neutrophil capture by activated platelets. 15, 16, 18 We therefore determined whether PDE4 inhibition altered the adhesive behavior of neutrophils by testing the effect of PDE-class-specific inhibitors on the formation of platelet-neutrophil mixed cell aggregates in suspension. The selective PDE4 inhibitors rolipram and RO2017-24 were compared with the mixed PDE3/4 inhibitor zardaverine, the Rolipram inhibits Src family kinase-mediated prolinerich tyrosine kinase 2 (Pyk2) phosphorylation in neutrophils exposed to soluble P-selectin. A, Neutrophils were pretreated with either rolipram or PP2 (both 10 μmol/L) alone or in combination with H89 (10 μmol/L) or dimethyl sulfoxide for 2 minutes at 37°C and then exposed to soluble P-selectin (10 μg/mL) for 2 minutes at 37°C with constant stirring at 1000 rpm. Samples were lysed in reducing Laemmli buffer, boiled for 10 minutes, and then diluted 1:20 with 1% Triton X-100 lysis buffer containing protease and phosphatase inhibitors. Pyk2 was immunoprecipitated with 10 μg/mL specific antibody at 4°C overnight. Immunoprecipitates were separated by 7.5% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with the phosphotyrosine-specific antibody (PY99) or anti-Pyk2 antibodies. Rolipram promotes protein kinase A (PKA)-mediated protein phosphorylation in neutrophils interacting with soluble P-selectin. Neutrophils were treated with rolipram and calyculin A (10 μmol/L) in the presence of either H89 or vehicle control (dimethyl sulfoxide) for 2 minutes at 37°C and then exposed for 2 additional minutes to soluble P-selectin. Immunoblot was first performed with an antibody that recognizes proteins phosphorylated on serines or threonines within the PKA consensus motif sequence K/RK/RXS/T followed by an anti-COOH-terminal Src kinase (Csk) antibody (A). Alternatively, samples were run in duplicates, and immunoblot was performed in parallel with the antibody that recognizes proteins phosphorylated on serines or threonines within the PKA consensus motif sequence K/RK/ RXS/T and by the anti-Csk antibody (B PDE5 inhibitor metoxyquinazoline, and the PDE3 inhibitor cilostamide. To exclude direct effects of the inhibitors on platelet function, platelets were loaded with a fluorescent probe, activated with thrombin receptor-activating peptide, and fixed with paraformaldehyde before coincubation with treated neutrophils. 36 Neutrophils were treated with vehicle or varying concentrations of PDE inhibitors for 2 minutes at 37°C and then coincubated with fixed platelets. The number of mixed cell aggregates was quantified by flow cytometry. As shown in Figure 3A , PDE4, but not PDE3 or PDE5 inhibition, dose-dependently prevented the formation of platelet-neutrophil aggregates. The effects of PDE4 inhibition were reversed by PKA blockade in a dose-dependent manner ( Figure 3B ). Next, we determined the ability of PDE4 blockade to inhibit neutrophil recruitment under flow conditions ( Figure 4A ). Neutrophils pretreated for 2 minutes at 37°C with PDE inhibitors were perfused over a platelet layer at a shear stress of 2 dyn/ cm 2 for 2 minutes. The surface was then perfused with media for an additional 2 minutes at a shear stress of 20 dyn/cm 2 to establish shear-resistant neutrophil-platelet interactions. The number of neutrophils remaining firmly adherent was measured during the last 20 seconds of high shear perfusion. PDE4 inhibitors, rolipram and zardaverine, but not PDE3 inhibitor cilostamide reduced neutrophil firm adhesion on spread platelets under shear ( Figure 4B ). Furthermore, the effect of rolipram was completely reversed by H89 ( Figure 4C) .
The results in both the mixed cell aggregation and shear perfusion system indicate that Mac-1-mediated firm adhesion of neutrophils to activated platelets can be prevented by PDE4 inhibitors. To define the role of Mac-1 in rolipram-mediated inhibition of neutrophil recruitment to adherent platelets, neutrophils were isolated from wild-type (WT) or Mac-1deficient mice and perfused over adherent WT or P-selectindeficient platelets. As expected, the total number of interacting cells was similar when WT or Mac-1 −/− neutrophils were perfused across WT platelets, and no interactions occurred along P-selectin −/− platelets ( Figure 5A ). In addition, Mac1 −/− neutrophils had substantially lower firm adhesion to platelets at the higher shear, whereas rolipram reduced firm adhesion of WT neutrophils without affecting firm adhesion of Mac-1 −/− neutrophils ( Figure 5B ). Activation of Mac-1 can be monitored by antibody CBRM1/5, which specifically recognizes epitopes of the integrin exposed after conformational changes that enable the integrin to recognize the ligands. 37 Exposure of neutrophils to P-selectin elicited CBRM1/5 epitope expression, and this conformational change in Mac-1 was prevented by rolipram ( Figure 5C ). These results suggest that PDE4 regulates Mac-1-dependent platelet-neutrophil adhesion by preventing activation-dependent conformational changes in Mac-1.
Rolipram Reduces Neutrophil Recruitment at the Site of Vascular Injury In Vivo
SFK signaling is required for both neutrophil adhesion to platelets and leukocyte recruitment at the site of arterial injury. 18 To determine whether PDE4 inhibition would upregulate an intrinsic check of SFK-mediated signaling in vivo, we investigated the ability of rolipram to inhibit platelet-neutrophil interactions at the site of vascular injury in a femoral injury model in mice. Animals were treated with rolipram or vehicle before endothelial denudation, and the number of leukocytes accumulated at the site of damage was evaluated 1 hour after injury. As depicted in Figure 6 , the accumulation of leukocytes along the arterial wall was significantly reduced by rolipram treatment. Figure 5 . The effect of rolipram on neutrophil recruitment to adherent platelets is mediated by inhibition of Mac-1. Bone marrow neutrophils and blood platelets were isolated from wild-type (WT), Mac-1 −/− , or P-selectin −/− mice (n=5). Neutrophils 5×10 6 /mL were perfused over a platelet surface at a shear stress of 2 dyn/cm 2 for 2 minutes. This was followed by perfusion of media for 2 minutes at 20 dyn/cm 2 . A, WT or Mac-1-deficient neutrophils were perfused over WT or P-selectin −/− platelets. Graphs display the total number of neutrophils interacting with the platelet surface 2 minutes after perfusion at 2 dyn/cm 2 . B, WT or Mac-1 −/− neutrophils were treated with rolipram (10 μmol/L). The number of neutrophils remaining firmly adhered at shear stress of 20 dyn/cm 2 is displayed. C, Human neutrophils were treated with rolipram (1 μmol/L) or vehicle for 2 minutes at 37°C and stimulated with soluble P-selectin (10 μg/mL) at 37°C without stirring for 10 minutes in the presence of isotype-matched phycoerytrin (PE) antibody or PE-conjugated CBRM1/5, which specifically recognizes epitopes of the integrin molecule that are exposed only after activation-dependent conformational changes. After stimulation, neutrophils were fixed in 2% paraformaldheyde for 30 minutes, washed, and analyzed by flow cytometry. Histograms are from one representative experiment. The bar graph depicts the increase in CBRM1/5 binding (mean fluorescent intensity; mean±SEM of 3 independent experiments) over that observed in resting neutrophils. DMSO indicates dimethyl sulfoxide; Neg, negative; and P-sel, P-selectin.
Discussion
The involvement of neutrophils in the pathogenesis of cardiovascular disease is strongly supported by epidemiological and experimental studies, leading to speculation about the potential benefit of therapeutics aimed at decreasing leukocyte count in high-risk populations. 38 The interaction of neutrophils with activated platelets drives much of their involvement in vascular pathology. 13 Studies have consistently indicated that neutrophil-platelet interactions occur at sites of vascular injury, atherosclerotic plaque, and arterial and venous thrombi [9] [10] [11] and contribute to exacerbate atherosclerosis 9 and promote thrombus formation by providing neutrophil-derived procoagulant tissue factor and NETs (neutrophil extracellular traps). 39, 40 Furthermore, in animal models of vascular injury, the lack of Mac-1 10 or P-selectin 11 reduces neointima hyperplasia. Both Mac-1 and P-selectin are essential for neutrophil recruitment, suggesting that accumulation of neutrophils at sites of vascular injury may promote the development of intimal hyperplasia. In contrast, other studies indicate that neutrophils can attenuate neointimal formation, mainly through the release of cathelicidin (or LL-37) that promotes re-endothelization. 41 Whether the role of neutrophils is the same in settings where platelets (or endothelium) are present or absent is not currently known.
Identifying novel targets to inhibit platelet-mediated neutrophil recruitment, at the site of vascular injury or thrombus formation, could have broad-ranging clinical benefits. We report that PDE4 inhibitors reduce the ability of neutrophils to interact with activated platelets and provide a compelling mechanistic explanation for this effect. Furthermore, we provide data that validate this approach in a preclinical model.
After the initial binding of platelet P-selectin to neutrophil PSGL-1, firm adhesion is established by the interaction between leukocyte Mac-1 and its platelet counter receptor glycoprotein Ibα, a process regulated by SFK. 18, 22, 42, 43 Unfortunately, therapeutic strategies based on either receptorligand pair inhibition or SFK blockade have been difficult to implement in clinical settings.
Because SFK activity can be negatively regulated by cAMP signaling in several cell systems, we sought to determine whether neutrophil response, that occurs on interaction with platelets, was similarly regulated by intracellular pools of cAMP that are sensitive to PDE inhibition.
Previous studies in T lymphocytes demonstrated that PKA phosphorylates Csk on serine 364 within the PKA substrate motif KKFS (Lys-Lys-Phe-Ser) and that this phosphorylation increases Csk activity to downregulate the activity of Lck. 26 We found that the PDE4 inhibitor, rolipram, blocks phosphorylation of Pyk2, the main downstream SFK effector, and triggers PKA-mediated phosphorylation of several proteins, including the SFK regulator Csk. Furthermore, PDE4 inhibition reduces neutrophil-platelet interactions in vitro by inhibiting Mac-1 activation, as measured by binding of an antibody that specifically recognizes neoepitopes exposed after conformational changes of activated integrin 37 and prevents platelet-mediated neutrophil recruitment along arterial wall after denudation injury.
PDE4 inhibitors may also reduce endothelial adhesive molecules in inflammation models. 32, 35 However, in the endovascular injury model used in the present study, endothelium is severely damaged and does not play a significant role in neutrophil recruitment. 44 Together, our data imply that there is a PDE4-sensitive pool of cAMP in neutrophils and support a model in which cAMP-PKA-Csk axis negatively regulates SFK activity after binding to P-selectin and serves as an intrinsic check to sustained neutrophil-platelet adhesion. Thus, PDE4 inhibitors may represent a novel therapeutic strategy to counteract the detrimental consequences of platelet-neutrophil interactions in the context of vascular disease and atherothrombosis.
Rolipram was marketed and used for treatment of depression, and recently the new PDE4 inhibitor roflumilast was approved for clinical use in patients with chronic obstructive pulmonary disease. 45, 46 Patients with chronic obstructive pulmonary disease are at heightened risk of developing ischemic cardiovascular events. 47 Importantly, a meta-analysis of the incidence of cardiovascular events in clinical trials with roflumilast in chronic obstructive pulmonary disease suggested that drug treatment was associated with a significant reduction in the rate of composite major cardiovascular events, 48 supporting the concept that PDE4 inhibition may offer beneficial effects by interfering with molecular events underlying cardiovascular disease and thrombosis. Our results provide novel mechanistic insight into potential therapeutic benefits for PDE4 inhibitors that may be achieved by preventing neutrophil recruitment to activated platelets and suggest that PDE inhibition can represent a new therapeutic strategy for the treatment and prevention of cardiovascular disease.
